Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires New Shares in Biomea Fusion, Inc. $BMEA

by · The Cerbat Gem

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 631,465 shares of the company’s stock, valued at approximately $783,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. XTX Topco Ltd increased its holdings in Biomea Fusion by 77.1% in the third quarter. XTX Topco Ltd now owns 265,303 shares of the company’s stock valued at $536,000 after purchasing an additional 115,524 shares during the last quarter. Scientech Research LLC bought a new stake in Biomea Fusion in the third quarter valued at about $25,000. Mariner LLC bought a new stake in Biomea Fusion in the third quarter valued at about $483,000. Virtu Financial LLC bought a new stake in Biomea Fusion in the third quarter valued at about $39,000. Finally, Two Sigma Investments LP increased its holdings in Biomea Fusion by 61.0% in the third quarter. Two Sigma Investments LP now owns 562,968 shares of the company’s stock valued at $1,137,000 after purchasing an additional 213,321 shares during the last quarter. Institutional investors own 96.72% of the company’s stock.

Biomea Fusion Price Performance

Shares of Biomea Fusion stock opened at $1.42 on Friday. Biomea Fusion, Inc. has a 1 year low of $0.87 and a 1 year high of $3.08. The business has a 50-day moving average of $1.54 and a two-hundred day moving average of $1.38. The company has a market capitalization of $102.66 million, a P/E ratio of -2.09 and a beta of -0.32.

Biomea Fusion (NASDAQ:BMEA – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.07. On average, equities analysts anticipate that Biomea Fusion, Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BMEA shares. Citizens Jmp started coverage on Biomea Fusion in a report on Tuesday, May 5th. They issued a “market outperform” rating and a $9.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a report on Monday, April 20th. Wall Street Zen upgraded Biomea Fusion from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Citigroup assumed coverage on Biomea Fusion in a report on Tuesday, May 5th. They issued an “outperform” rating for the company. Finally, D. Boral Capital restated a “buy” rating and issued a $12.00 price target on shares of Biomea Fusion in a report on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.29.

View Our Latest Analysis on BMEA

About Biomea Fusion

(Free Report)

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.

See Also

Want to see what other hedge funds are holding BMEA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report).